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Summary
 
Human histocompatibility leukocyte antigen (HLA)-E is a nonclassical HLA class I molecule,
the gene for which is transcribed in most tissues. It has recently been reported that this mole-
cule binds peptides derived from the signal sequence of HLA class I proteins; however, no
function for HLA-E has yet been described. We show that natural killer (NK) cells can recog-
nize target cells expressing HLA-E molecules on the cell surface and this interaction results in
inhibition of the lytic process. Furthermore, HLA-E recognition is mediated primarily through
the CD94/NKG2-A heterodimer, as CD94-specific, but not killer cell inhibitory receptor
(KIR)–specific mAbs block HLA-E–mediated protection of target cells. Cell surface HLA-E
could be increased by incubation with synthetic peptides corresponding to residues 3–11 from
the signal sequences of a number of HLA class I molecules; however, only peptides which con-
tained a Met at position 2 were capable of conferring resistance to NK-mediated lysis, whereas
those having Thr at position 2 had no effect. Interestingly, HLA class I molecules previously
correlated with CD94/NKG2 recognition all have Met at residue 4 of the signal sequence (po-
sition 2 of the HLA-E binding peptide), whereas those which have been reported not to inter-
act with CD94/NKG2 have Thr at this position. Thus, these data show a function for HLA-E
and suggest an alternative explanation for the apparent broad reactivity of CD94/NKG2 with
HLA class I molecules; that CD94/NKG2 interacts with HLA-E complexed with signal se-
quence peptides derived from “protective” HLA class I alleles rather than directly interacting
with classical HLA class I proteins.
 
I
 
n humans, there are three classical class I MHC mole-
cules (HLA-A, -B, and -C). These molecules consist of a
peptide bound to a transmembrane glycoprotein subunit,
the heavy chain, in association with a soluble light chain,
 
b
 
2
 
-microglobulin (1). Nonclassical MHC class I molecules
show homology to classical class I molecules but generally
have limited polymorphism, low cell surface expression,
and more restricted tissue distribution (2). The function of
these nonclassical class I molecules remains unclear, but
some of them may have more specialized antigen presenta-
tion activities, e.g., mouse H2-M3 presents 
 
N
 
-formylated
peptides (3). In humans, the nonclassical HLA-G molecule
binds a wide range of peptides derived from cellular pro-
teins and has been suggested to play an important role in
the maintenance of maternal tolerance to the fetus by inter-
acting with inhibitory receptors on NK cells (4). HLA-E is
another nonclassical class I molecule and, like classical
MHC class I loci, the HLA-E gene is highly transcribed in
many tissues (5–7). Mouse cell lines transfected with HLA-E
and human 
 
b
 
2
 
-microglobulin generally exhibit low levels
of cell surface expression, which has been attributed to a
lack of appropriate endogenous peptides (8). Recent in
vitro studies have shown that HLA-E can bind peptides de-
rived from the signal sequences of certain HLA class I mol-
ecules and that the primary peptide anchor residues are at
positions 2 and 9 (9).
NK cells are one of the three lineages of lymphocytes
and are thought to control viral infections and tumor de-
velopment (10). They are capable of killing MHC class I
negative target cells without prior sensitization. Further-
more, the expression of class I molecules on target cells
renders them resistant to lysis by most NK cells (11). Inhib-
itory receptors expressed by human NK cells belong to ei-
ther the immunoglobulin (killer cell inhibitory receptor;
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KIR) or the C-type lectin superfamily. The best character-
ized members of the KIR family contain two (p58 mole-
cules: CD158) or three (p70 molecules: NKB1) immuno-
globulin-like domains and different receptors of this family
bind defined groups of classical HLA class I molecules (12,
13). The second family of receptors is composed of two
subunits: CD94 paired with one member of the NKG2
family of proteins. The CD94–NKG2-A heterodimer trans-
mits signals that lead to the inhibition of the lytic process.
Numerous studies suggest that this heterodimer recognizes
a broad panel of classical HLA class I molecules (14–19).
Recognition of nonclassical HLA class I molecules by
NK cells has been recently described. Specifically, numer-
ous reports suggest that HLA-G can confer protection from
lysis to otherwise sensitive target cells, although the identity
of the receptors involved in this interaction remains con-
troversial (20–24). In this study we examined whether an-
other nonclassical class I molecule, HLA-E, can be recog-
nized by NK cells. Our results show that NK cells can
interact with HLA-E complexed with specific peptides on
target cells and that this recognition is mediated, at least
partially, if not solely, by CD94–NKG2.
 
Materials and Methods
 
Reagents, Peptides, and mAbs.
 
Media and supplements were
purchased from BioFluids (Rockville, MD) and FCS from Hy-
clone (Logan, UT). G418 and Hygromycin B were obtained
from GIBCO BRL (Baltimore, MD). Recombinant IL-2 was a
gift from Hoffman-LaRoche (Nutley, NJ). Peptides (Table 1)
were synthesized and purified as previously described (25). The
following mAbs were used: B9.12.1 (anti–HLA class I); GL183
(anti-CD158b); EB6 (anti-CD158a); HP-3B1 (anti-CD94; all
from Immunotech, Westbrook, ME); 3G8 (anti-CD16 from
PharMingen, San Diego, CA); Leu-19 (anti-CD56; from Bec-
ton-Dickinson, San Jose, CA); UCHT1 (anti-CD3; from
DAKO, Carpinteria, CA); and fluorescein-labeled goat anti–
mouse IgG F(ab
 
9
 
)
 
2
 
 (from the Jackson Immunoresearch Laborato-
ries, West Grove, PA).
 
Cell lines and NK Cells.
 
The human mutant lymphoblastoid
cell lines 721.221 and 721.221 transfected with HLA-Cw
 
*
 
0304
(named here as 721.221-Cw3) have been previously described
(26). The murine transporter associated with antigen processing
(TAP)-2–deficient RMA-S cell line was obtained from Dr.
Marika Pla (INSERM, Hopital St. Louis, Paris, France). Cells
were cotransfected by electroporation with 15 
 
m
 
g of a BamHI-
linearized 15-kb BamHI/SalI subclone of the human 
 
b
 
2
 
-micro-
globulin gene in pUC19 (27), together with 5 
 
m
 
g of a Sal I-lin-
earized derivative of the Cos203 vector (28), in which the EBV
sequences and Cos sites had been deleted by Eca digestion and
that contained either no insert or a HindIII/BglII fragment of
cosmid cd3.14 (7) encoding the HLA-E
 
*
 
01033 allele. Transfec-
tants expressing human 
 
b
 
2
 
-microglobulin alone (referred to here
as RMA-S) or human 
 
b
 
2
 
-microglobulin and HLA-E
 
*
 
01033
(RMA-S/HLA-E) were selected in complete RPMI supple-
mented with 0.4 mg/ml of Hygromycin B. NK leukocytosis
221707 cells were provided by Dr. J.P. Houchins (Department of
Laboratory Medicine and Pathology, University of Minnesota,
Minneapolis, MN; 29). NK clones from healthy donors were ob-
tained and grown as previously described (18).
 
Immunostaining.
 
Target cells were incubated at 26
 
8
 
C or 37
 
8
 
C
overnight in 5% CO
 
2
 
 in the absence or presence of saturating
amounts of the indicated peptide (300 
 
m
 
M). Cells were then
washed and analyzed for HLA class I expression by flow cytome-
try using the B9.12.1 mAb. All NK clones were CD3
 
2
 
, CD56
 
1
 
,
CD16
 
1
 
, and CD94
 
1
 
.
 
Cytotoxicity Assays.
 
Target cells were prepared as described
for immunostaining, except that for the last 90–120 min the cells
were labeled with sodium [
 
51
 
Cr]chromate (DuPont, Charlotte,
NC). The cytotoxic activity of NK cells was assayed in a 4-h
 
51
 
Cr-release assay as previously described (18, 30).
 
Results and Discussion
 
The 721.221 cell line that does not express HLA-A, -B,
-C, or -G has been shown to express the nonclassical class I
 
Table 1.
 
Peptides Used in this Study
 
Name Sequence Protein of origin and position in the intact protein
MAGE EADPTGHSY MAGE-1 161-169
RT ILKEPVHGV HIV-1 RT 476-484
B27 VTAPRTLLL HLA-B
 
*
 
1301, -B
 
*
 
1801, -B
 
*
 
2705
 
§
 
, -B
 
*
 
3701, -B
 
*
 
4002, -B
 
*
 
4402,
-B
 
*
 
4701, -B
 
*
 
5401, -B
 
*
 
5501, and -B
 
*
 
5601 leader sequences 3–11
 
‡
 
B15 VTAPRTVLL HLA-B
 
*
 
1501, -B
 
*
 
3501, -B
 
*
 
4101, -B
 
*
 
4501, -B
 
*
 
4601, -B
 
*
 
4901,
-B
 
*
 
5001, -B
 
*
 
5101, -B
 
*
 
5201, -B
 
*
 
5301, -B
 
*
 
5701, -B
 
*
 
5801, 
and -B
 
*
 
7801 leader sequences 3-11
 
‡
 
B7 VMAPRTVLL
 
HLA-B
 
*
 
0702
 
i
 
, 
 
-B
 
*
 
0801
 
, 
 
-B
 
*
 
1401
 
, -B
 
*
 
1402, -B
 
*
 
3901, -B
 
*
 
3902, -B
 
*
 
4201, 
and -B
 
*
 
4801 leader sequences 3–11
 
‡
 
Cw3 VMAPRTLIL HLA-Cw
 
*
 
0302, 
 
-Cw
 
*
 
0304
 
, 
 
-Cw
 
*
 
0401
 
, 
 
-Cw
 
*
 
0801
 
, -Cw
 
*
 
1201, -Cw
 
*
 
1401,
and -Cw
 
*
 
0602 leader sequences 3–11
 
‡
‡
 
This list is derived from the SWISS-PROT database using the PROWL search program (http://prowl.rockefeller.edu), but does not include all
HLA class I molecules that possess these leader sequences.
 
§
 
HLA class I molecules previously reported not to interact with CD94–NKG2 are underlined (14–16, 34).
 
i
 
HLA class I molecules previously described to confer CD94–NKG2–mediated target cell protection are shown in bold (14–16, 34). 
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molecule HLA-E (9). This ability to express HLA-E could
explain the low but detectable level of HLA class I mole-
cules on the surface of these cells when they are grown at
37
 
8
 
C (data not shown). In vitro studies suggest that HLA-
E, like its murine homologue Qa-1b (31), binds signal se-
quence–derived peptides (9). In an attempt to increase cell
surface expression of HLA-E, four synthetic peptides de-
rived from the signal sequences of classical HLA class I
molecules and two control peptides (see Table 1) were in-
dividually incubated with 721.221 cells. When the incuba-
tion was performed at 37
 
8
 
C, no significant change in the
cell surface expression of HLA class I molecules was ob-
served (data not shown). Since the incubation of a murine
cell line transfected with HLA-E at 26
 
8
 
C increased its ex-
pression on the cell surface (8), 721.221 cells were incu-
bated with these peptides at 26
 
8
 
C. Under these conditions
the signal sequence–derived peptides induced a small, but
reproducible increase in class I cell surface expression (Fig.
1 
 
A
 
). The melanoma-associated antigen (MAGE) and re-
verse transcriptase (RT) peptides did not enhance the class I
expression with respect to cells incubated without peptides,
in agreement with previous data indicating that these two
peptides do not bind HLA-E (9). Thus, cell surface expres-
sion of HLA-E can be enhanced on 721.221 cells by incu-
bation with appropriate peptides at 26
 
8
 
C.
Although NK recognition of the nonclassical HLA-G
molecules has recently been a focus of attention, NK rec-
 
ognition of other nonclassical class I molecules has not been
reported. Previous data have shown that 721.221 cells are
susceptible to NK lysis (14–16), indicating that the small
amount of HLA-E expressed on the surface of these cells is
not sufficient to inhibit NK-mediated lysis or that the
HLA-E is not complexed with the appropriate peptide(s).
To determine whether HLA-E could serve as a ligand for
NK receptors, 721.221 cells were cultured with the pep-
tides described above before their use as target cells in cyto-
toxicity assays with 221707 NK cells. When incubated at
37
 
8
 
C, 721.221 cells were susceptible to NK–mediated lysis
in both the presence and absence of peptides (data not
shown). However, when target cells were incubated with
peptide at 26
 
8
 
C, NK-mediated lysis was dramatically inhib-
ited by the B7 and Cw3 peptides. This decrease in lysis was
comparable to that obtained by transfection of 721.221
cells with HLA-Cw
 
*
 
0304 (Fig. 1 
 
B
 
). Incubation with the
other four peptides had no effect on lysis. These data sug-
gest that HLA-E in association with specific peptides can be
recognized by NK cells, even when the levels of class I ex-
pression are relatively low (compare the class I expression
on 721.221 cells in the presence of B7 and Cw3 peptides
with that on 721.221-Cw3 cells in Fig. 1 
 
A
 
).
To eliminate the possibility that other HLA-like mole-
cules (e.g., HLA-F) expressed by 721.221 cells are involved
in NK cell recognition, we made use of murine RMA-S
Figure 1. Cell surface expres-
sion of HLA-E molecules com-
plexed with HLA class I signal-
sequence derived peptides confers
protection against NK cell–
mediated lysis. (A) 721.221 target
cells were incubated in the ab-
sence or presence of the indicated
peptides at 268C and analyzed for
HLA class I expression. The empty
histograms correspond to the sec-
ondary antibody (goat anti–mouse)
alone  and the filled histograms
show the binding of the HLA
class I–specific mAb B9.12.1.
The histogram in the lower right
hand corner shows the HLA class
I expression on 721.221 cells
transfected with HLA-Cw*0304.
The mean fluorescence channel
of B9.12.1 staining is shown in-
side the boxes. (B) 221707 NK
cells were assayed for cytotoxic-
ity against 721.221 target cells
incubated with or without the
indicated peptides at 268C or
721.221-Cw3 cells. The E/T ra-
tio was 15:1 and the percentage
of specific lysis shown is the av-
erage of three experiments. The
standard deviation was ,10%.
Figure 2. Expression of HLA-E
by RMA-S cells with appropri-
ate peptides confers resistance to
NK-mediated lysis. (A) RMA-
S/HLA-E cells were incubated
in the absence or presence of the
indicated peptide at 378C and
analyzed for cell surface HLA
class I expression. The empty
histograms represent secondary
Ab controls (goat anti–mouse)
and the filled histograms show
the binding of the B9.12.1 mAb.
The histogram in the lower right
hand corner shows staining of
RMA-S cells transfected with
human b2-microglobulin alone.
The mean fluorescence channel
of B9.12.1 staining is shown in-
side the boxes. (B) 221707 NK
cells were assayed for cytotoxic-
ity against RMA-S and RMA-S/
HLA-E cells incubated in the
presence or absence of the indi-
cated peptides at 378C. The E/T
ratio was 40:1.816 HLA-E Recognition by CD94–NKG2 on NK Cells
cells transfected with HLA-E. Incubation with appropriate
peptides increased the levels of class I expression on these
cells both at 268C (data not shown) and at 378C (Fig. 2 A).
Although all four class I signal sequence–derived peptides
induced HLA-E expression in comparison to the two con-
trol peptides, only the B7 and Cw3 peptides induced resis-
tance to NK-mediated lysis (Fig. 2 B). These results clearly
show that HLA-E molecules can provide protection from
NK-mediated lysis. The observation that only the B7 and
Cw3 peptides protected target cells from lysis, suggests a
degree of peptide specificity. The biochemical basis for the
observed “peptide specificity” remains to be determined.
To identify the inhibitory receptor involved in HLA-E–
mediated protection from NK cell lysis, we made use of anti-
CD94 and anti-CD158 specific mAbs and a panel of NK
clones. The 221707 NK cells used in the above experiments
are CD158a2 and CD158b2, but express the inhibitory
CD94–NKG2-A heterodimer as determined by immuno-
blot and redirected antibody-dependent cellular cytotoxic-
ity assay (data not shown). CD94–NKG2-A has been im-
plicated in the recognition of a broad panel of HLA class I
molecules including the nonclassical class I molecule HLA-G
(14–17, 22–24). Thus, we examined whether anti-CD94
mAb could block the protection conferred on target cells
by peptide-induced stabilization of HLA-E. The presence
of anti-CD94 mAb did not affect the levels of lysis ob-
tained in the presence of both B27 and B15 peptides. In
contrast, the addition of anti-CD94 mAb blocked the inhi-
bition of lysis conferred by the B7 and Cw3 peptides, sug-
gesting that CD94–NKG2-A is the receptor involved in
HLA-E recognition (Fig. 3).
To determine if members of the KIR family were in-
volved in HLA-E recognition, three NK clones were stud-
ied: D2 (CD941, CD158a2, CD158b2); D7 (CD941,
CD158a1, CD158b1); and AR46 (CD941, CD158a1,
CD158b1). NK clone D2 has the same phenotype as the
221707 NK cells used above. Consequently, the addition
of anti-CD94 mAb restored NK-mediated lysis when
HLA-E was complexed with a protective peptide. Similar
data were obtained with the CD158a1, CD158b1 NK
clone D7; once again the presence of anti-CD94 mAb re-
stored lysis. In contrast, the addition of anti-CD158a and
anti-CD158b mAb had no effect on lysis, suggesting that
CD158a and CD158b receptors did not interact with
HLA-E. Finally, data obtained from NK clone AR46 con-
firmed that the CD158a and CD158b receptors were not
involved in HLA-E recognition (Fig. 4). The AR46 NK
clone kills target cells incubated with the Cw3 peptide de-
spite the presence of the inhibitory CD158a and CD158b
molecules. No CD94–NKG2 mediated protection was ob-
served in AR46 cells, as they express a CD94–NKG2 re-
ceptor that activates NK killing as determined by rADCC
(data not shown). The ligation of CD94 on NK cells has
been previously shown to provide either activation or inhi-
bition of NK cell lysis, depending on the NK clone. These
divergent responses depend on the particular NKG2 pro-
tein associated with CD94; although NKG2-A transmits
negative signals leading to the inhibition of the cytolytic
activity, signaling through NKG2-C is thought to activate
NK cells (19, 23, 32, 33).
The CD94–NKG2-A inhibitory NK receptor has been
previously implicated in the recognition of a broad panel of
HLA class I molecules, but little is known about the struc-
tural basis for this interaction. Previous data has shown that
the low levels of cell surface expression of HLA-E was lim-
ited, at least in part, by the lack of appropriate peptides (8),
and that a potential source of such peptides are the signal
sequences of certain class I molecules (9). It is worth noting
that the molecules encoded by transfected HLA class I genes
Figure 3. HLA-E mediated protection is blocked by anti-CD94 mAb.
721.221 target cells were incubated with or without the indicated pep-
tides at 268C and then used in a cytotoxicity assay with 221707 NK cells
in the presence of anti-CD94 or control antibodies at a final concentra-
tion of 10 mg/ml. The E/T ratio was 15:1.
Figure 4. HLA-E is not recognized by CD158a and CD158b KIR re-
ceptors. 721.221 target cells were incubated at 268C with or without the
Cw3 peptide and then used in a cytotoxicity assay with the indicated NK
clones (D2, D7, and AR46) in the presence of anti-CD94, anti-CD158a,
or anti-CD158b mAb at a final concentration of 10 mg/ml. The E/T ra-
tio was 5:1. nd, not determined.817 Borrego et al. Brief Definitive Report
that apparently interact with CD94–NKG2-A all possess
Met at position 4 of the signal sequence, whereas those al-
leles that do not confer resistance all encode Thr at the
same position (14–16). This suggests an alternative explana-
tion for the apparently broad reactivity of CD94–NKG2-A
with HLA class I molecules, namely that CD94–NKG2-A
interacts directly with HLA-E complexed with peptides
derived from the signal sequence of HLA class I molecules.
Overexpression of transfected classical HLA class I alleles in
the HLA-A–, -B–, and -C–negative, but HLA-E–positive
721.221 cells likely provides sufficient leader sequence–
derived peptides to increase the levels of cell surface HLA-E
to protect the otherwise sensitive targets. Moreover, the
use of anti-HLA class I mAb to reverse the protection in-
duced by classical HLA class I molecules may in fact be due
to antibody masking of HLA-E rather than of the trans-
fected HLA class I allele.
These data demonstrate a novel mechanism by which
NK cells can monitor self-HLA class I expression through
the recognition of HLA class I–derived peptides in the con-
text of HLA-E. This may be important in preventing au-
toreactivity of NK cells, in particular by NK cells that lack
KIR specific for self HLA class I molecules.
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